U.S. markets closed

Stereotaxis, Inc. (STXS)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
3.3900-0.0300 (-0.88%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close3.4200
Open3.4600
Bid3.3300 x 4000
Ask3.5600 x 800
Day's Range3.3700 - 3.4900
52 Week Range1.7000 - 5.8200
Volume67,554
Avg. Volume195,840
Market Cap248.345M
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-0.0930
Earnings DateAug 06, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Benzinga

    Insider Sells Stereotaxis Stock

    Shares of Stereotaxis, Inc. (AMEX:STXS) fell by 2.9% from the previous closing price. A Form 4 filing filed with the SEC on Wednesday, September 16 showed that Benfer David sold 4,999 shares at an average price of $4.34. The transaction moved the executive's stake in Stereotaxis, Inc. Common Stock Inc. to 155,001 shares.Why Insider Transactions Are Important? Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision.When an insider buys stock after an important sell off, that can indicate the insider's faith in the success of the organization. Henceforth, if the stock is bought at new highs, it might be because the insider feels that the stock is not overvalued. Insiders who sell stock at new lows could be anticipating some capitulation moment. If the insider sells at new highs, it could point to the intention to "take some profit" and "lock in a gain."Important Transaction Codes Wall Street tends to focus on insider transactions which take place in the open market, viewed inside a Form 4 filing via codes P for purchase and S for sale. An open-market transaction means the insider went into the market of their own volition and made an active decision about the potential path for a company and its stock moving forward.Transaction codes besides P or S aren't relatively important as they are seldom tied to a decision by the executive. For example, transaction code A is indicative of an insider being forced to sell shares to attain compensation. Moreover, transaction code C indicates the conversion of an option.See more from Benzinga * Insider Buys Quotient's Stock * Insider Sells American Woodmark's Stock * Insider Sells MetroCity Bankshares Stock(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    First Hospitals in the World Adopt Genesis Robotic Technology for Cardiac Heart Rhythm Disorders

    ST. LOUIS, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced it has completed installations of the world’s first Genesis Robotic Magnetic Navigation (RMN) systems to treat heart rhythm disorders at Helsinki University Hospital in Finland and Banner - University Medicine Heart Institute in Phoenix, Arizona. “The clinical benefits of robotics in electrophysiology have been extensively documented at our hospital over many years,” said Dr. Pekka Raatikainen, Chief of Electrophysiology and Pacing at the Heart and Lung Center at Helsinki University Central Hospital. “With the adoption of the first Genesis systems in the world, we are proud to be a pioneer in the process of advancing robotic technology for the benefits of patients and the medical community.”“The capabilities of robotics are growing at a rapid rate, moving us toward a paradigm shift in our practice,” said Dr. J. Peter Weiss, Director of Ventricular Arrhythmia Management and Robotics at Banner - University Medicine Heart Institute. “I am extremely excited to play a part in bringing this advanced technology to our community of patients and heart rhythm specialists throughout Phoenix and beyond.”Robotic Magnetic Navigation introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias, abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, certain arrhythmias can significantly increase the risk of stroke, heart failure, and sudden cardiac arrest. The Genesis RMN® system provides the established benefits and reliability of RMN in a highly innovative architecture that is faster, smaller, lighter, and more flexible. Adopting the Genesis RMN system reflects a commitment to using the most advanced technologies to enhance patient care.“Patients with medical conditions from the most complex to the most common seek us out for care in part because we remain on the cutting edge in technology and safety,” said Kristi McShay, Assistant Vice President for the Cardiovascular Line at Banner Health. “We are pleased to be the first in the nation to offer this new generation of robotics for treating heart rhythm disorders.”“This technology allows us to positively address the increasing number of patients with complex arrhythmias. In addition, it provides us a competitive advantage to other Nordic centers concerning education and learning,” said Antti Vento, Medical Director of Helsinki Heart and Lung Center.About Stereotaxis Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe,” “estimate,” “project,” “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to continue to manage expenses and cash burn rate at sustainable levels, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States, including changes in government reimbursement of procedures, dependence upon third-party vendors, timing of regulatory approvals, the impact of the recent coronavirus (COVID-19) pandemic and our response to it, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.Company Contacts: David L. Fischel Chairman and Chief Executive OfficerKimberly Peery Chief Financial Officer314-678-6100 investors@stereotaxis.com

  • Health Check: How Prudently Does Stereotaxis (NYSEMKT:STXS) Use Debt?
    Simply Wall St.

    Health Check: How Prudently Does Stereotaxis (NYSEMKT:STXS) Use Debt?

    Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...